Zacks Research Issues Optimistic Outlook for Clorox Earnings

The Clorox Company (NYSE:CLX) – Equities researchers at Zacks Research increased their Q4 2025 earnings per share estimates for shares of Clorox in a research report issued on Monday, May 19th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $2.23 for the quarter, up from their prior estimate of $2.14. The consensus estimate for Clorox’s current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox’s Q1 2026 earnings at $1.52 EPS, Q2 2026 earnings at $1.51 EPS, Q3 2026 earnings at $1.57 EPS, FY2026 earnings at $6.71 EPS, Q1 2027 earnings at $1.62 EPS, Q2 2027 earnings at $1.71 EPS and Q3 2027 earnings at $1.70 EPS.

Several other equities research analysts also recently commented on the stock. UBS Group reduced their target price on shares of Clorox from $176.00 to $154.00 and set a “neutral” rating on the stock in a research note on Thursday, April 17th. Evercore ISI set a $140.00 price target on Clorox and gave the stock an “underperform” rating in a research report on Tuesday, May 6th. Citigroup cut their price objective on Clorox from $165.00 to $150.00 and set a “neutral” rating for the company in a research report on Monday, April 14th. JPMorgan Chase & Co. lowered their target price on Clorox from $151.00 to $144.00 and set a “neutral” rating for the company in a research note on Tuesday, May 6th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $150.00 price objective on shares of Clorox in a research report on Thursday, January 30th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $151.23.

Clorox Price Performance

Clorox stock opened at $135.53 on Wednesday. The business has a 50 day simple moving average of $140.57 and a 200 day simple moving average of $152.97. Clorox has a one year low of $127.60 and a one year high of $171.37. The company has a market capitalization of $16.70 billion, a PE ratio of 37.03, a price-to-earnings-growth ratio of 2.62 and a beta of 0.60. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.12). The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The company’s quarterly revenue was down 8.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.71 EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CLX. Brooklyn Investment Group lifted its holdings in Clorox by 163.8% during the 4th quarter. Brooklyn Investment Group now owns 153 shares of the company’s stock valued at $25,000 after purchasing an additional 95 shares during the last quarter. Redwood Park Advisors LLC acquired a new stake in shares of Clorox during the 4th quarter worth about $26,000. Millstone Evans Group LLC bought a new stake in shares of Clorox during the 4th quarter worth about $31,000. Wood Tarver Financial Group LLC bought a new stake in shares of Clorox during the 4th quarter worth about $31,000. Finally, Asset Planning Inc bought a new position in Clorox in the 4th quarter valued at about $32,000. 78.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber acquired 4,000 shares of the company’s stock in a transaction on Wednesday, May 7th. The shares were purchased at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $546,280. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.57% of the stock is currently owned by corporate insiders.

Clorox Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 9th. Investors of record on Wednesday, April 23rd were given a $1.22 dividend. This represents a $4.88 dividend on an annualized basis and a dividend yield of 3.60%. The ex-dividend date of this dividend was Wednesday, April 23rd. Clorox’s dividend payout ratio is currently 87.61%.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.